Sagar Lonial awarded Gray Family Chair in Cancer at Winship

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Sagar Lonial, chief medical officer for Winship Cancer Institute of Emory University and chairman of the Department of Hematology and Medical Oncology, was presented with the Anne and Bernard Gray Family Chair in Cancer.

The endowment honors the life of Gray’s sister, Karen Ammons Howell, who died of breast cancer.

Lonial is an expert in the biology and care of patients with multiple myeloma. His most recent research focuses on combining novel agents as therapy for myeloma patients and how to identify new targets and treatment strategies for patients with high-risk myeloma.

He was principal investigator on two large studies of novel monoclonal antibodies, both of which led to FDA approval. The research team he developed has contributed to all the major FDA approvals for myeloma therapeutics over the past decade. Lonial is currently leading a global genome sequencing study for patients with newly diagnosed myeloma.

Table of Contents

YOU MAY BE INTERESTED IN

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login